HUM 233
Alternative Names: HUM-233Latest Information Update: 28 Nov 2023
At a glance
- Originator 180 Life Sciences; Hebrew University of Jerusalem; University of Oxford
- Class Analgesics; Anti-inflammatories; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammation in USA (Intraperitoneal)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Pain in USA (Intraperitoneal)
- 22 Nov 2021 HUM 233 is still in preclinical trials in Inflammation and Pain in USA (Intraperitoneal)